Compare JONE & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JONE | ABEO |
|---|---|---|
| Founded | 2021 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.0M | 282.5M |
| IPO Year | 2026 | 2005 |
| Metric | JONE | ABEO |
|---|---|---|
| Price | $9.86 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.56 |
| AVG Volume (30 Days) | 80.6K | ★ 2.1M |
| Earning Date | N/A | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $675.42 |
| Revenue Next Year | N/A | $126.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $9.80 | $2.09 |
| 52 Week High | $9.92 | $7.65 |
| Indicator | JONE | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 56.13 | 27.45 |
| Support Level | $9.81 | N/A |
| Resistance Level | $9.92 | $5.77 |
| Average True Range (ATR) | 0.00 | 0.33 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 50.00 | 16.27 |
Jones Ventures INTL Acquisition1 Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.